Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 83
Filtrar
1.
Br J Dermatol ; 190(4): 510-518, 2024 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-37976235

RESUMO

BACKGROUND: Several registries for hidradenitis suppurativa (HS) already exist in Europe and the USA. There is currently no global consensus on a core dataset (CDS) for these registries. Creating a global HS registry is challenging, owing to logistical and regulatory constraints, which could limit opportunities for global collaboration as a result of differences in the dataset collected. The solution is to encourage all HS registries to collect the same CDS of information, allowing registries to collaborate. OBJECTIVES: To establish a core set of items to be collected by all HS registries globally. The core set will cover demographic details, comorbidities, clinical examination findings, patient-reported outcome measures and treatments. METHODS: Beginning in September 2022, 20 participants - including both clinicians with expertise in HS and patient advocates - from eight countries across three continents participated in a Delphi process consisting of four rounds of voting, with all participants completing each round. A list of potential items for inclusion in the core set was generated from the relevant published literature, including systematic reviews of comorbidities in HS, clinical and examination findings, and epidemiology. For disease severity and progression items, the Hidradenitis SuppuraTiva Core outcome set International Collaboration (HiSTORIC) core set and other relevant instruments were considered for inclusion. This resulted in 47 initial items. Participants were invited to suggest additional items to include during the first round. Anonymous feedback was provided to inform each subsequent round of voting to encourage consensus. RESULTS: The eDelphi process established a CDS of 48 items recommended for inclusion in all HS registries globally. CONCLUSIONS: The routine adoption of this CDS in current and future HS registries should allow registries in different parts of the world to collaborate, enabling research requiring large numbers of participants.


Assuntos
Hidradenite Supurativa , Humanos , Consenso , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/epidemiologia , Hidradenite Supurativa/terapia , Resultado do Tratamento , Técnica Delphi , Sistema de Registros
2.
Dermatology ; 240(3): 369-375, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38354718

RESUMO

INTRODUCTION: Data concerning the global burden of hidradenitis suppurativa (HS) are limited. Reported prevalence estimates vary between 0.0003% and 4.1%, and data from various geographical regions are still to be collected. Previously reported prevalences have been limited by the methodological approach and source of data. This has resulted in great heterogeneity as prevalence data from physician-diagnosed cases poorly match those of self-reported apparent HS disease. METHODS: The Global Hidradenitis Suppurativa Atlas (GHiSA) introduces an innovative approach to determine the global prevalence of HS. This approach involves using a previously validated questionnaire to screen apparently healthy adults accompanying a patient to a non-dermatological outpatient clinic visit in a hospital or a private/family medicine clinic. The screening questionnaire (i.e., the index test) is combined with a subsequent physician-based in-person validation (i.e., the reference standard) of the participants who screen positive. Approximately ten percent of the screen-negative participants are also clinically assessed to verify the diagnostic precision of the test. The local prevalence (pi) will be estimated from each country that submits the number of patients who are HS positive according to the index test and clinical examination (n), and the corresponding total number of observations (N). CONCLUSION: The GHiSA Global Prevalence studies are currently running simultaneously in 58 countries across six continents (Africa, Europe, Australia, North America, South America, and Asia). The goal of the combined global proportion is the generation of a single summary (i.e., proportional meta-analysis), which will be done after a logit transformation and synthesized using a random-effects model. The novel standardization of the Global Prevalence Studies conducted through GHiSA enables direct international comparisons, which were previously not possible due to substantial heterogeneity in past HS prevalence studies.


Assuntos
Saúde Global , Hidradenite Supurativa , Humanos , Hidradenite Supurativa/epidemiologia , Hidradenite Supurativa/diagnóstico , Prevalência , Inquéritos e Questionários , Adulto
3.
Emerg Med J ; 2024 Sep 09.
Artigo em Inglês | MEDLINE | ID: mdl-39251339

RESUMO

Hidradenitis suppurativa (HS) is a complex, chronic skin disease characterised by painful inflammatory nodules, abscesses, dermal tunnels, sinus tracts and fistulae with a predilection for intertriginous skin. HS carries a substantial disease burden due to its prevalence, associated comorbidities and quality of life impacts and is associated with high healthcare resource utilisation. Clarity regarding the prevalence and pathogenesis of HS has led to improved therapies and more patients seeking care in both outpatient and acute care settings, including the emergency department. Emergency medicine providers play a critical role in HS diagnosis, management of acute flares and connection of HS patients with long-term dermatologic care, which can in turn help manage utilisation of acute care resources.

4.
J Am Acad Dermatol ; 86(5): 1092-1101, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-33493574

RESUMO

BACKGROUND: Hidradenitis suppurativa (HS) is associated with comorbidities that contribute to poor health, impaired life quality, and mortality risk. OBJECTIVE: To provide evidence-based screening recommendations for comorbidities linked to HS. METHODS: Systematic reviews were performed to summarize evidence on the prevalence and incidence of 30 comorbidities in patients with HS relative to the general population. The screening recommendation for each comorbidity was informed by the consistency and quality of existing studies, disease prevalence, and magnitude of association, as well as benefits, harms, and feasibility of screening. The level of evidence and strength of corresponding screening recommendation were graded by using the Strength of Recommendation Taxonomy (SORT) criteria. RESULTS: Screening is recommended for the following comorbidities: acne, dissecting cellulitis of the scalp, pilonidal disease, pyoderma gangrenosum, depression, generalized anxiety disorder, suicide, smoking, substance use disorder, polycystic ovary syndrome, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, hypertension, cardiovascular disease, inflammatory bowel disease, spondyloarthritis, and sexual dysfunction. It is also recommended to screen patients with Down syndrome for HS. The decision to screen for specific comorbidities may vary with patient risk factors. The role of the dermatologist in screening varies according to comorbidity. LIMITATIONS: Screening recommendations represent one component of a comprehensive care strategy. CONCLUSIONS: Dermatologists should support screening efforts to identify comorbid conditions in HS.


Assuntos
Hidradenite Supurativa , Síndrome Metabólica , Pioderma Gangrenoso , Canadá/epidemiologia , Comorbidade , Feminino , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/epidemiologia , Hidradenite Supurativa/etiologia , Humanos , Síndrome Metabólica/epidemiologia , Pioderma Gangrenoso/epidemiologia
5.
Am J Obstet Gynecol ; 224(1): 54-61, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32980357

RESUMO

Hidradenitis suppurativa is a chronic inflammatory disease that disproportionately affects women of childbearing age. Hidradenitis suppurativa is characterized by painful nodules, abscesses, draining dermal tunnels, and scarring with a predilection for intertriginous sites, such as the axilla, groin, and breast regions. Delay in diagnosis and treatment of hidradenitis suppurativa often results in long-term sequelae leading to significant morbidity, and rarely mortality, in these patients. This clinical opinion suggests that obstetrician-gynecologists are uniquely poised to recognize early signs of hidradenitis suppurativa during routine well-woman examinations and initiate treatment or referral to dermatology. Herein, we provide clinical pearls for obstetrician-gynecologists caring for female patients with hidradenitis suppurativa, including strategies for comprehensive management and recommendations to improve the comfort of patients with hidradenitis suppurativa during examinations.


Assuntos
Hidradenite Supurativa/diagnóstico , Axila , Mama , Árvores de Decisões , Feminino , Virilha , Hidradenite Supurativa/tratamento farmacológico , Humanos , Saúde da Mulher
6.
Exp Dermatol ; 28(1): 94-103, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30484907

RESUMO

The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent innovations, practical challenges and potential solutions to issues related in the management and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the disease.


Assuntos
Anti-Infecciosos/uso terapêutico , Procedimentos Cirúrgicos Dermatológicos , Hidradenite Supurativa/etiologia , Hidradenite Supurativa/terapia , Anti-Inflamatórios/uso terapêutico , Pesquisa Biomédica , Comorbidade , Hidradenite Supurativa/diagnóstico por imagem , Hidradenite Supurativa/epidemiologia , Humanos , Incidência , Qualidade de Vida , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Ultrassonografia
9.
J Am Acad Dermatol ; 81(1): 91-101, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30872149

RESUMO

Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.


Assuntos
Antagonistas de Androgênios/uso terapêutico , Antibacterianos/uso terapêutico , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/tratamento farmacológico , Imunossupressores/uso terapêutico , Guias de Prática Clínica como Assunto , Administração Oral , Administração Tópica , Canadá , Medicina Baseada em Evidências , Feminino , Humanos , Injeções Intralesionais , Masculino , América do Norte , Prognóstico , Publicações , Medição de Risco , Resultado do Tratamento , Estados Unidos
10.
J Am Acad Dermatol ; 81(1): 76-90, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30872156

RESUMO

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.


Assuntos
Produtos Biológicos/uso terapêutico , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/terapia , Guias de Prática Clínica como Assunto , Antibacterianos , Canadá , Terapias Complementares , Procedimentos Cirúrgicos Dermatológicos/métodos , Quimioterapia Combinada , Medicina Baseada em Evidências , Feminino , Humanos , Imunossupressores/uso terapêutico , Masculino , América do Norte , Editoração , Medição de Risco , Índice de Gravidade de Doença , Estados Unidos
14.
J Immunol ; 197(9): 3490-3503, 2016 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-27694491

RESUMO

Although chronic graft-versus-host disease (CGVHD) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathogenesis is limited. To identify the main operant pathways across the spectrum of CGVHD, we analyzed gene expression in circulating monocytes, chosen as in situ systemic reporter cells. Microarrays identified two interrelated pathways: 1) IFN-inducible genes, and 2) innate receptors for cellular damage. Corroborating these with multiplex RNA quantitation, we found that multiple IFN-inducible genes (affecting lymphocyte trafficking, differentiation, and Ag presentation) were concurrently upregulated in CGVHD monocytes compared with normal subjects and non-CGVHD control patients. IFN-inducible chemokines were elevated in both lichenoid and sclerotic CGHVD plasma and were linked to CXCR3+ lymphocyte trafficking. Furthermore, the levels of the IFN-inducible genes CXCL10 and TNFSF13B (BAFF) were correlated at both the gene and the plasma levels, implicating IFN induction as a factor in elevated BAFF levels in CGVHD. In the second pathway, damage-/pathogen-associated molecular pattern receptor genes capable of inducing type I IFN were upregulated. Type I IFN-inducible MxA was expressed in proportion to CGVHD activity in skin, mucosa, and glands, and expression of TLR7 and DDX58 receptor genes correlated with upregulation of type I IFN-inducible genes in monocytes. Finally, in serial analyses after transplant, IFN-inducible and damage-response genes were upregulated in monocytes at CGVHD onset and declined upon therapy and resolution in both lichenoid and sclerotic CGVHD patients. This interlocking analysis of IFN-inducible genes, plasma analytes, and tissue immunohistochemistry strongly supports a unifying hypothesis of induction of IFN by innate response to cellular damage as a mechanism for initiation and persistence of CGVHD.


Assuntos
Doença Enxerto-Hospedeiro/imunologia , Interferons/metabolismo , Monócitos/fisiologia , Adulto , Apresentação de Antígeno , Fator Ativador de Células B/metabolismo , Diferenciação Celular , Movimento Celular/genética , Quimiocina CXCL10/metabolismo , Doença Crônica , Proteína DEAD-box 58/metabolismo , Feminino , Humanos , Imunidade Inata , Masculino , Pessoa de Meia-Idade , Receptores CXCR3/metabolismo , Receptores Imunológicos , Receptores de Reconhecimento de Padrão/metabolismo , Transdução de Sinais , Receptor 7 Toll-Like/metabolismo , Transplante Homólogo , Adulto Jovem
18.
Semin Cutan Med Surg ; 36(2): 41, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28538741

RESUMO

Hidradenitis suppurativa (HS) is a prevalent and devastating inflammatory skin disease predominating in women and minorities. HS is characterized by painful recurrent abscesses, foul-smelling purulent drainage, sinus tract and fistula formation, and disfiguring scarring involving intertriginous body sites including the axillae, breasts, groin, and buttocks. Disease onset typically occurs in the second to fourth decades of life and is associated with significant impacts on physical and psychological well-being due to pain, shame, and isolation, leading to profound suffering and despair. HS is both clinically and biologically understudied and therefore poorly understood. As a result, no uniformly effective therapies exist for management, and until recently, there was a paucity of high-level evidence to support current treatments.


Assuntos
Hidradenite Supurativa , Humanos
19.
Semin Cutan Med Surg ; 36(2): 79-85, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28538749

RESUMO

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent painful nodules and abscesses involving intertriginous areas. Repeated episodes of profound inflammation in HS can lead to a number of complications, causing significant morbidity and decreasing quality of life. Complications of HS may affect the skin alone or may have systemic impact. Cutaneous complications of HS include sinus tracts, fistulae, scarring and contractures, squamous cell carcinoma, and lymphedema. Systemic complications of HS include chronic pain, systemic amyloidosis, and possibly anemia. Preventing disease complications by controlling primary disease is a key component of HS management. Clinicians should be prepared to recognize complications early, as prompt management is necessary to minimize negative impacts.


Assuntos
Hidradenite Supurativa/complicações , Carcinoma de Células Escamosas/etiologia , Humanos , Dermatopatias/etiologia , Neoplasias Cutâneas/etiologia
20.
Arterioscler Thromb Vasc Biol ; 35(12): 2667-76, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26449753

RESUMO

OBJECTIVE: To understand whether directly measured psoriasis severity is associated with vascular inflammation assessed by (18)F-fluorodeoxyglucose positron emission tomography computed tomography. APPROACH: In-depth cardiovascular and metabolic phenotyping was performed in adult psoriasis patients (n=60) and controls (n=20). Psoriasis severity was measured using psoriasis area severity index. Vascular inflammation was measured using average aortic target-to-background ratio using (18)F-fluorodeoxyglucose positron emission tomography computed tomography. RESULTS: Both the psoriasis patients (28 men and 32 women, mean age 47 years) and controls (13 men and 7 women, mean age 41 years) were young with low cardiovascular risk. Psoriasis area severity index scores (median 5.4; interquartile range 2.8-8.3) were consistent with mild-to-moderate skin disease severity. Increasing psoriasis area severity index score was associated with an increase in aortic target-to-background ratio (ß=0.41, P=0.001), an association that changed little after adjustment for age, sex, and Framingham risk score. We observed evidence of increased neutrophil frequency (mean psoriasis, 3.7±1.2 versus 2.9±1.2; P=0.02) and activation by lower neutrophil surface CD16 and CD62L in blood. Serum levels of S100A8/A9 (745.1±53.3 versus 195.4±157.8 ng/mL; P<0.01) and neutrophil elastase-1 (43.0±2.4 versus 30.8±6.7 ng/mL; P<0.001) were elevated in psoriasis. Finally, S100A8/A9 protein was related to both psoriasis skin disease severity (ß=0.53; P=0.02) and vascular inflammation (ß=0.48; P=0.02). CONCLUSIONS: Psoriasis severity is associated with vascular inflammation beyond cardiovascular risk factors. Psoriasis increased neutrophil activation and neutrophil markers, and S100A8/A9 was related to both skin disease severity and vascular inflammation.


Assuntos
Aortite/diagnóstico , Fluordesoxiglucose F18 , Imagem Multimodal/métodos , Ativação de Neutrófilo , Neutrófilos/imunologia , Tomografia por Emissão de Pósitrons , Psoríase/diagnóstico , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Adulto , Aortite/sangue , Aortite/diagnóstico por imagem , Aortite/imunologia , Biomarcadores/sangue , Estudos de Casos e Controles , Feminino , Humanos , Imunidade Inata , Mediadores da Inflamação/sangue , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos , Psoríase/sangue , Psoríase/imunologia , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA